Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-01-16 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
2024年年度业绩预亏公告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast announcement by Heyuan Biotech (Shanghai) Co., Ltd. It provides preliminary estimated financial results for the full year 2024, including expected revenue and net profit/loss ranges, and compares them to the previous year. It explicitly states that the data are preliminary, unaudited, and subject to change upon the formal audited annual report release. The document length is 1828 characters, which is relatively short and consistent with an earnings release or earnings forecast rather than a full annual report. The document does not contain full financial statements or detailed analysis but rather a summary of expected financial performance. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is ER with high confidence. FY 2024
2025-01-16 Chinese
2025年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2025 年第一次临时股东大会会议资料" which translates to "2025 First Extraordinary General Meeting (EGM) Meeting Materials." It contains detailed meeting instructions, agenda, and proposals for shareholder approval, including changes to registered capital, board size, and amendments to company bylaws. The content is clearly materials prepared for a shareholders' meeting, including procedural rules and agenda items, rather than a report or announcement of results. It is not a full annual or interim report, nor an earnings release or audit report. It is not a voting results announcement but the meeting materials themselves. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings). The document length is about 4710 characters, consistent with detailed meeting materials rather than a brief announcement.
2025-01-13 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司董事、高级管理人员暨核心技术人员辞任并新增认定核心技术人员事项的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed verification opinion from Haitong Securities regarding the resignation and appointment of directors, senior management, and core technical personnel at Heyuan Biotechnology (Shanghai) Co., Ltd. It includes biographical details, shareholding information, legal compliance references, and the impact of personnel changes on the company. The document is not an annual or interim financial report, nor is it an earnings release or audit report. It is not a call transcript or investor presentation. The content focuses on management and board changes, specifically resignations and new appointments of directors and senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3833 characters, which is sufficient for a detailed announcement rather than a brief notice. Hence, the classification is MANG with high confidence.
2025-01-07 Chinese
关于变更注册资本、调整董事会成员人数、修订《公司章程》及《董事会议事规则》并办理工商变更登记的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from the company regarding changes to its registered capital, adjustment of the number of board members, and amendments to the company's articles of association and board meeting rules. It includes details about stock option exercises affecting registered capital, changes in board size, and revisions to governance documents. The document is a formal public notice of these corporate governance and capital structure changes, not a full report or financial statement. It does not contain comprehensive financial data or detailed management discussion but rather announces corporate structural changes and related filings. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related governance adjustments.
2025-01-07 Chinese
关于部分董事、监事、高级管理人员、核心技术人员变更及调整董事会审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from a company regarding changes in its board of directors, senior management, and core technical personnel. It details resignations, appointments, and adjustments to the board audit committee and supervisory board representatives. There is no financial data, earnings information, or report publication mentioned. The content focuses on personnel changes and governance structure updates. Therefore, it fits the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about management changes, not just a brief notice or regulatory filing.
2025-01-07 Chinese
和元生物技术（上海）股份有限公司章程
Regulatory Filings
2025-01-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.